Effect of BEMER Magnetic Field Therapy on the Level of Fatigue in Patients with Multiple Sclerosis: A Randomized, Double-Blind Controlled Trial

被引:33
|
作者
Piatkowski, Joachim [2 ]
Kern, Simone [1 ]
Ziemssen, Tjalf [1 ]
机构
[1] Tech Univ Dresden, MS Ctr Dresden, Dept Neurol, D-01307 Dresden, Germany
[2] Neurol Outpatient Ctr, Dresden, Germany
关键词
WEAK ELECTROMAGNETIC-FIELDS; DEFINITION; RESOLUTION; IMPACT;
D O I
10.1089/acm.2008.0501
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objectives: Electromagnetic field therapy has been reported to be beneficial in patients with multiple sclerosis (MS) with significant fatigue. This study was designed to evaluate the long-term effects of Bio-Electro-Magnetic-Energy- Regulation (BEMER) on MS-related fatigue. Design: This was a monocenter, patient- and rater-blinded, placebo-controlled trial. Patients: There were 37 relapsing-remitting patients with MS with significant fatigue in the study. Intervention: The intervention consisted of BEMER magnetic field treatment for 8 minutes twice daily in comparison to placebo for 12 weeks. Outcome measures: The primary outcome criterion was change in the Modified Fatigue Impact Scale (MFIS) between baseline and 12 weeks. The secondary outcome criteria were changes of the Fatigue Severity Scale (FSS), a general depression scale-long version (ADS-L), Multiple Sclerosis Functional Scale (MSFC), and the Expanded Disability Status Scale (EDSS). Results: There was evidence of a significant difference of MFIS value (primary outcome criterion) after 12 weeks in favor of the verum group (26.84 versus 36.67; p = 0.024). In addition, FSS values were significantly lower in the verum group after 12 weeks (3.5 versus 4.7; p = 0.016). After 6 weeks' follow-up, verum and placebo groups did not differ in experienced fatigue (MFIS, FSS). Regarding the subscales of the MFIS, there was a significant decrease in physical (p = 0.018) and cognitive (p = 0.041), but not in psychologic subscales only in the verum group regarding the timepoints baseline and 12 weeks. BEMER therapy was well tolerated. Discussion: In this pilot study, we were able to demonstrate a beneficial effect of BEMER intervention on MS fatigue. As this was only a pilot study, trials with more patients and longer duration are mandatory to describe long-term effects.
引用
收藏
页码:507 / 511
页数:5
相关论文
共 50 条
  • [21] A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis
    Miller, AE
    Morgante, LA
    Buchwald, LY
    Coyle, PK
    Krupp, LB
    Doscher, CA
    Lublin, FD
    Knobler, RL
    Trantas, F
    Kelley, L
    Smith, CR
    LaRocca, N
    Lopez, S
    NEUROLOGY, 1997, 48 (02) : 312 - 314
  • [22] Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis
    Brochet, Bruno
    Deloire, Mathilde S. A.
    Perez, Paul
    Loock, Timothe
    Baschet, Louise
    Debouverie, Marc
    Pittion, Sophie
    Ouallet, Jean-Christophe
    Clavelou, Pierre
    de Seze, Jerome
    Collongues, Nicolas
    Vermersch, Patrick
    Zephir, Helene
    Castelnovo, Giovanni
    Labauge, Pierre
    Lebrun, Christine
    Cohen, Mikael
    Ruet, Aurelie
    PLOS ONE, 2017, 12 (01):
  • [23] Static magnetic field therapy for symptomatic diabetic neuropathy: A randomized, double-blind, placebo-controlled trial
    Weintraub, MI
    Wolfe, GI
    Barohn, RA
    Cole, SP
    Parry, GJ
    Hayat, G
    Cohen, JA
    Page, JC
    Bromberg, MB
    Schwartz, SL
    ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 2003, 84 (05): : 736 - 746
  • [24] N-Acetyl Cysteine for Fatigue in Progressive Multiple Sclerosis: A Pilot Randomized Double-Blind Placebo-Controlled Trial
    Krysko, Kristen M.
    Bischof, Antje
    Nourbakhsh, Bardia
    Henry, Roland G.
    Revirajan, Nisha
    Manguinao, Michael F.
    Li, Yan
    Waubant, Emmanuelle
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 51 - 52
  • [25] A double-blind randomized controlled trial of toremifen therapy for mastalgia
    Gong, C
    Song, EW
    Jia, WJ
    Qin, L
    Guo, JJ
    Jia, HX
    Hu, XQ
    Su, FX
    ARCHIVES OF SURGERY, 2006, 141 (01) : 43 - 47
  • [26] N-acetyl cysteine for fatigue in progressive multiple sclerosis: a pilot randomized double-blind placebo-controlled trial
    Krysko, K. M.
    Bischof, A.
    Nourbakhsh, B.
    Henry, R. G.
    Revirajan, N.
    Manguinao, M.
    Li, Y.
    Waubant, E.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 345 - 346
  • [27] Safety and efficacy of memantine for multiple sclerosis-related fatigue: A pilot randomized, double-blind placebo-controlled trial
    Falsafi, Zeinab
    Tafakhori, Abbas
    Agah, Elmira
    Mojarrad, Maryam
    Dehghani, Reihaneh
    Ghaffarpour, Majid
    Aghamollaii, Vajiheh
    Mousavi, Seyed Vahid
    Fouladi, Zahra
    Pourghaz, Bahareh
    Balali, Pargol
    Harirchian, Mohammad Hossein
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2020, 414
  • [28] N-acetyl cysteine for fatigue in progressive multiple sclerosis: A pilot randomized double-blind placebo-controlled trial
    Krysko, Kristen
    Bischof, Antje
    Nourbakhsh, Bardia
    Henry, Roland
    Revirajan, Nisha
    Manguinao, Michael
    Li, Yan
    Waubant, Emmanuelle
    NEUROLOGY, 2019, 92 (15)
  • [29] Ginseng in the treatment of fatigue in multiple sclerosis: a randomized, placebo-controlled, double-blind pilot study
    Etemadifar, Masoud
    Sayahi, Farnaz
    Abtahi, Seyed-Hossein
    Shemshaki, Hamidreza
    Dorooshi, Gholam-Ali
    Goodarzi, Mohammad
    Akbari, Mojtaba
    Fereidan-Esfahani, Mahboobeh
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2013, 123 (07) : 480 - 486
  • [30] Ginseng in the treatment of fatigue in multiple sclerosis: a randomized, placebo-controlled, double-blind pilot study
    Fereidan-Esfahani, Mahboobeh
    Etemadifar, Masoud
    Sayahi, Farnaz
    Abtahi, Seyed-Hossein
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 936 - 936